First Time Loading...

Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 994 GBX 0.66% Market Closed
Updated: May 11, 2024
Section:
 

Relative Value

The Relative Value of one HIK stock under the Base Case scenario is 5 997.05 GBX. Compared to the current market price of 1 994 GBX, Hikma Pharmaceuticals PLC is Undervalued by 67%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIK Relative Value
Base Case
5 997.05 GBX
Undervaluation 67%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
69
vs Industry
55
Median 3Y
1.9
Median 5Y
2.3
Industry
2.5
Forward
0
More Details
29.1
P/E
P/E
Price to Earnings
29.1
vs History
9
vs Industry
17
Median 3Y
17.2
Median 5Y
15.7
Industry
23.4
Forward
0.1
More Details
9.1
P/OCF
P/OCF
Price to OCF
9.1
vs History
68
vs Industry
38
Median 3Y
9
Median 5Y
10.4
Industry
17.9
More Details
22.5
P/FCFE
P/FCFE
Price to FCFE
22.5
vs History
47
vs Industry
21
Median 3Y
21.9
Median 5Y
22
Industry
24.1
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
58
vs Industry
32
Median 3Y
2.4
Median 5Y
2.7
Industry
2.1
More Details
31.4
EV/S
EV/S
Enterprise Value to Sales
31.4
vs History
28
vs Industry
7
Median 3Y
31.3
Median 5Y
25.3
Industry
2.6
Forward
0.3
More Details
64.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
64.1
vs History
28
vs Industry
4
Median 3Y
64
Median 5Y
49.8
Industry
5.2
More Details
102.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
102.4
vs History
19
vs Industry
3
Median 3Y
98.4
Median 5Y
93.8
Industry
13.9
Forward
1.1
More Details
145.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
145.1
vs History
28
vs Industry
2
Median 3Y
144.9
Median 5Y
112.7
Industry
17.5
Forward
1.3
More Details
148.4
EV/OCF
EV/OCF
Enterprise Value to OCF
148.4
vs History
38
vs Industry
2
Median 3Y
155.2
Median 5Y
131
Industry
16.4
More Details
223.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
223.3
vs History
47
vs Industry
3
Median 3Y
262
Median 5Y
223
Industry
18.1
More Details
23.2
EV/IC
EV/IC
Enterprise Value to IC
23.2
vs History
28
vs Industry
6
Median 3Y
23.2
Median 5Y
17
Industry
1.9
More Details

Multiples Across Competitors

HIK Competitors Multiples
Hikma Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.4B GBP 1.9 29.1 102.4 145.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.7
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average P/E: 51
29.1
194%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
HIK intrinsic value, competitors valuation, and company profile.
DCF Valuation
HIK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HIK stock valuation using valuation multiples.
Wall Street Estimates
HIK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HIK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.